Aging is not a single process. It is the convergence of at least twelve distinct biological failure modes. Addressing one while ignoring the others yields incomplete results. The Blast Whole-Body Rejuvenation Protocol intervenes across every major axis.
Aging is written into the epigenome as accumulating dysregulation, silencing repair genes and activating senescence pathways. Our PSC exosomes carry Yamanaka factors that partially reverse this drift without destabilizing cell identity.
PSC · ExosomesLow-grade systemic inflammation drives virtually every age-related disease. LAV-BPIFB4 counteracts it at the endothelial level; Klotho suppresses NF-κB; exosomes clear SASP from senescent cells systemically.
LAV-BPIFB4 · Klotho · ExosomesEvery organ depends on blood supply. VEGF-A rebuilds tissue vasculature. LAV-BPIFB4 restores eNOS-mediated nitric oxide production and pericyte function, addressing both structural and signaling dimensions.
VEGF-A · LAV-BPIFB4Mitochondrial decline precedes most symptoms of aging. FGF21 stimulates mitochondrial biogenesis and promotes metabolic flexibility. Klotho protects against oxidative damage system-wide.
FGF21 · Klotho · ExosomesSenescent cells accumulate with age, secreting SASP factors that poison surrounding tissue. PSC exosomes carrying OCT4, SOX2, and NANOG can reactivate dormant repair programs and reduce the senescence burden across multiple organs.
PSC · Exosomes · KlothoFollistatin, by blocking myostatin and activin A, restores muscle synthesis signaling. FGF21 further supports lean mass preservation and metabolic efficiency, together preserving the physical reserve that predicts longevity outcomes.
Follistatin · FGF21In 2006, Shinya Yamanaka discovered that four transcription factors, OCT4, SOX2, KLF4, and c-MYC, could reverse adult cells to a pluripotent, embryonic-like state. The Nobel Prize followed in 2012. The longevity implications took longer to appreciate.
Subsequent research showed that partial expression of Yamanaka factors, not enough to fully reprogram cells, but enough to reset epigenetic age, could reverse aging markers without loss of cell identity. In one landmark study, systemic delivery of OSK (Oct4, Sox2, Klf4) in 124-week-old mice extended median remaining lifespan by 109% and significantly improved frailty scores. The epigenetic clock reversed. The animals were not just living longer, they were biologically younger.
The challenge with full OSKM reprogramming has always been safety: sustained expression of c-MYC carries oncogenic risk. The solution the field has converged on is transient, sub-reprogramming doses, enough to reset the epigenome, not enough to destabilize cell identity. This is precisely what our pluripotent stem cells and exosomes deliver.
PSC-derived exosomes carry OCT4, SOX2, KLF4, and NANOG as mRNA cargo. Primate studies confirm these mRNAs are delivered to recipient cells and transiently expressed, producing epigenetic reset signals without full reprogramming. No pluripotency is conferred. No teratoma risk. The exosome vehicle provides exactly the dose calibration that safe partial reprogramming requires.
Furthermore, in our PSC exosomes, these Yamanaka factors are expressed alongside the full pluripotency-supporting network, NANOG, LIN28, and endogenous co-regulators, that balances their activity, enhances their regenerative effects, and suppresses the oncogenic tendencies of c-MYC signaling. The natural exosome context is not just a delivery mechanism. It is a biological safety system.
Each of our minicircle gene therapies delivers a specific longevity factor, correcting the age-related decline of molecules your biology produced abundantly when young. Together, they form a coordinated molecular environment in which every other intervention performs better.
Klotho declines by ~80% between age 20 and 60. This drop removes the body's most potent systemic longevity factor, one that simultaneously protects the brain, kidneys, cardiovascular system, and every cell from oxidative stress and premature aging. Restoring Klotho is the closest thing in biology to a global anti-aging switch.
A single minicircle injection sustains physiological Klotho levels for approximately 12 months, improving synaptic plasticity, reducing neuroinflammation, protecting the renal tubule, preventing vascular calcification, and reducing cellular senescence throughout the body.
FGF21 orchestrates the body's entire metabolic response to nutritional and energetic stress, mimicking the benefits of caloric restriction, fasting, and exercise at the molecular level. Its decline with age is a primary driver of metabolic syndrome, fatty liver, insulin resistance, and the energy depletion that accelerates biological aging.
Elevated FGF21 stimulates mitochondrial biogenesis, promotes fat oxidation, reduces systemic metabolic inflammation, reverses hepatic steatosis, and extends lifespan in multiple animal models through activation of the PGC-1α/SIRT1 longevity axis.
Follistatin is the body's natural antagonist to myostatin and activin A, two powerful suppressors of muscle growth that increase dramatically with age. The result of this imbalance is sarcopenia: progressive muscle loss that drives frailty, metabolic decline, insulin resistance, and increased mortality risk from every major disease.
Follistatin gene therapy restores the natural muscle synthesis environment, enabling meaningful lean mass recovery even in older individuals, while reducing metabolic inflammation and improving insulin sensitivity through the muscle-fat axis.
Vascular aging, progressive capillary loss, endothelial dysfunction, and reduced tissue perfusion, is a root cause of every organ's declining function with age. When tissues receive less blood, they receive less oxygen, fewer nutrients, fewer regenerative signals, and accumulate more metabolic waste.
VEGF-A gene therapy drives angiogenesis at the tissue level, restoring the capillary networks that aging has dismantled. Science Advances identified VEGF-A as the first pharmacologically tractable master pathway for human organ rejuvenation, our minicircle delivers it with precise, local expression.
LAV-BPIFB4 is a gene variant found enriched in centenarians, individuals who reach 100 while compressing morbidity to the very end of life. It encodes a secreted protein that enhances endothelial function through eNOS activation and nitric oxide production, protecting against hypertension, atherosclerosis, diabetic cardiomyopathy, frailty, and inflammaging.
Gene therapy with LAV-BPIFB4 prevented cardiac deterioration in middle-aged mice and rescued cardiac function and myocardial perfusion in older mice by improving microvasculature density and pericyte coverage, the first gene therapy designed around a variant literally evolved by nature in those who age most successfully.
Each intervention creates biological conditions that make the others more effective. This is not additive medicine, it is synergistic. The whole is immeasurably greater than the sum of its parts.
Epigenetic reset, senescence, systemic repair
Amplified by VEGF-A (perfusion), LAV-BPIFB4 (vascular delivery), Klotho (senescence protection)
Delivers Yamanaka factors safely system-wide. Creates a regenerative microenvironment for every other therapy.
Neuroprotection, anti-senescence, anti-oxidant
Enhances exosome neural uptake, reduces inflammation impairing VEGF-A response, potentiates FGF21 metabolic effects
Systemic longevity anchor. Protects every other intervention's gains from oxidative and inflammatory erosion.
Metabolism, mitochondria, liver
Follistatin synergy improves muscle energy efficiency, Klotho potentiates insulin sensitivity, VEGF-A improves metabolic tissue perfusion
Creates the metabolic substrate for cellular repair. Without metabolic efficiency, regenerative signals cannot be executed.
Muscle, metabolic resilience, anti-frailty
FGF21 provides energy substrate, VEGF-A vascularizes recovering muscle, exosomes deliver anabolic signaling miRNAs
Restores physical reserve, the single strongest predictor of longevity outcomes across all-cause mortality.
Angiogenesis, tissue perfusion, skin & hair
Vascular highway for exosome distribution, enhances Klotho delivery to peripheral tissues, amplifies Follistatin muscle recovery
The delivery infrastructure of the entire protocol. Perfused tissues respond to every other therapy more effectively.
eNOS/NO, pericyte function, inflammaging
Complements VEGF-A at the endothelial signaling level, reduces inflammatory load impairing exosome efficacy, restores microvascular environment for Klotho distribution
Addresses what VEGF-A alone cannot: the cellular signaling quality of the endothelium itself.
Full-spectrum biological age reversal: epigenetic, vascular, metabolic, structural, and regenerative, simultaneously.
PSC exosomes deliver Yamanaka factors as transient mRNA, producing partial epigenetic reprogramming without teratoma risk. Confirmed in primate studies: OCT4, SOX2, KLF4, and NANOG are expressed in recipient cells, resetting gene expression toward a youthful pattern without conferring pluripotency.
PSC · Exosomes · NANOG + OSKNChronic low-grade inflammation is addressed from four simultaneous angles: Klotho suppresses NF-κB; LAV-BPIFB4 counteracts inflammaging via eNOS; FGF21 reduces metabolic inflammation; PSC exosomes clear SASP from senescent cells. No single anti-inflammatory agent achieves this breadth.
Klotho · LAV-BPIFB4 · FGF21 · ExosomesVEGF-A rebuilds capillary density at the tissue level. LAV-BPIFB4 restores eNOS-mediated nitric oxide production and pericyte coverage at the cellular level. Together they address both the structural and signaling dimensions of vascular aging, the infrastructure on which every other intervention depends.
VEGF-A · LAV-BPIFB4FGF21 mimics the metabolic benefits of caloric restriction at the molecular level, stimulating mitochondrial biogenesis, promoting fat oxidation, and restoring the PGC-1α/SIRT1 longevity axis. Follistatin preserves the lean mass through which metabolic health is maintained.
FGF21 · Follistatin · KlothoPluripotent stem cells delivered IV flood the system with regenerative signaling molecules, directing repair responses in every organ. The exosome cargo, Yamanaka factor mRNAs, growth factors, anti-inflammatory miRNAs, creates a global pro-regenerative environment that sustains the gains of every other therapy.
PSC · Exosomes · VEGF-APartial reprogramming is the frontier of longevity science. The Yamanaka factors our exosomes carry are the same molecular tools researchers are using to reverse biological age in animal models, with an additional safety feature that gene therapy vectors cannot provide: the natural dose calibration and co-regulatory balance of the exosome context.
At Blast Institute, we translate evidence into practice, carefully, rigorously, and years ahead of mainstream medicine.
Abstract Scleroderma — or systemic sclerosis — is one of the most relentless diseases in rheumatology. Not because it is
Abstract Few developments in the history of medicine have been as quietly revolutionary as adeno-associated virus (AAV) gene therapy. The
Abstract Most people in longevity medicine know Klotho for what it does to the aging clock — slowing it down,
Abstract Klotho is a longevity-associated protein primarily produced in the kidneys and known to regulate aging-related pathways including phosphate metabolism,
Finasteride slows hair loss — at a cost, and only for as long as you take it. A new generation
A landmark 2026 study in Alzheimer's & Dementia — the field's flagship journal — has established that higher circulating Klotho
The journey to peak human performance begins with a single, definitive decision. Schedule a Consultation with our founding clinicians to explore your eligibility for the Whole-Body Rejuvenation Program and begin designing your biological future.
The Art of Illusion Restoration Ideal for:
Creating the look of a fuller head of hair, adding density to thinning areas, or complementing a hair transplant by adding depth.
The Science:
This is a non-invasive cosmetic tattooing technique where we deposit micro-dots of pigment into the scalp to replicate the appearance of natural hair follicles.
Key Benefits:
Instant Camouflage: Effectively masks scalp visibility, creating the illusion of a closely shaved head or greater density.
No Downtime:
Results. A quick procedure with immediate visual
Versatile:
Excellent as a standalone solution or to enhance the results of other treatments.
Ideal for:
Advanced baldness (Norwood Scale III-VI), receding hairlines, and areas where follicles are no longer present.
The Science:
When follicles are permanently lost, we must redistribute them. We use the Follicular Unit Extraction (FUE) method to meticulously harvest genetically resistant hair follicles from the back of your scalp and implant them into the thinning areas.
Key Benefits:
Permanent, Natural Results: The transplanted hair is your own and will grow naturally for a lifetime.
Restores Hairlines and Density:
youthful frame for your face. Recreates a natural, Optimal Long-Term Solution: For significant loss, this is the gold standard. We often recommend combining a transplant with VEGF-A therapy to ensure the newly implanted grafts thrive and to protect the surrounding native hair.
Ideal for:
Moderate thinning, areas with poor circulation, and as a powerful adjunct to hair transplants.
The Science:
This is a groundbreaking treatment that addresses the vascular cause of hair loss. We use a non-integrating gene therapy vector to deliver the VEGF-A gene directly to your scalp cells. This gene instructs your body to produce new blood vessels (angiogenesis).
Key Benefits:
Ideal for:
Early-stage thinning, diffuse hair loss, and enhancing overall hair health.
The Science:
Our Pluripotent Exosomes (PXHair) are powerful signaling molecules harvested from embryonic stem cells. When applied after microneedling, they deliver a concentrated set of instructions to your dormant follicles.
Key Benefits:
Re-educates Follicles: Signals miniaturized follicles to re-enter the active growth (anagen) phase.
Empty fat cells, don’t destroy them. Our non-invasive red light therapy targets the mitochondria within your fat cells, enhancing their function and encouraging the release of stored lipids. This “fat-emptying” approach shrinks fat cells naturally, supports mitochondrial energy production, and contours the body without surgery, downtime, or the destruction of tissue.
Experience the future of weight management. While GLP-1 agonists manage appetite, our pioneering FGF21 minicircle gene therapy reengineers your metabolism itself. A single annual injection instructs your body to:
Follistatin plays a significant role in metabolic health by enhancing insulin sensitivity and promoting glucose uptake in muscle and adipose tissue, helping to maintain stable blood sugar levels and offering a promising approach for managing type 2 diabetes and metabolic syndrome. It also supports fat reduction by increasing muscle mass, which elevates basal metabolic rate, while encouraging the browning of white adipose tissue to boost energy expenditure and reduce fat storage. Additionally, follistatin provides hepatic protection by helping prevent fatty liver disease and fibrosis through the inhibition of pro-fibrotic TGF-β signaling.
The journey to metabolic health begins in the gut. We use targeted peptides and advanced Traditional Chinese Medicine (TCM) formulations to restore gut integrity, reduce inflammation, and optimize the critical communication between your digestive system and brain. This foundational work improves nutrient absorption, reduces cravings, and creates a balanced internal environment for lasting change.
Experience deep, targeted brainwave states with immersive sound, precise vibration, as well as specific light wavelengths to modulate brain activity. These non-invasive technology promote relaxation, reduce mental fatigue, and enhance overall cognitive clarity.
Peak brain function requires a balanced nervous system. We provide you with advanced wearables and AI-guided biofeedback protocols to optimize your Heart Rate Variability (HRV). By training your body’s stress response, you gain mastery over your mental state, improving focus, emotional regulation, and recovery.
The brain depends on a dense microvascular network to function optimally.
VEGF-A (Vascular Endothelial Growth Factor A) promotes:
Because VEGF-A acts locally, it has to be used in a targeted manner to stimulate vascular regeneration.
This rebuilds the biological infrastructure that supports brain performance.
Go beyond symptom management. We utilize specific peptides and the groundbreaking CN105 peptide, designed to provide powerful neuroprotective and cognitive-enhancing effects. This approach helps shield neurons from damage, reduce inflammation, and stimulate the repair of neural pathways, laying the foundation for a stronger, more resilient brain.
Cognitive decline is often driven by reduced cellular energy rather than neuron loss.
FGF21 (Fibroblast Growth Factor 21) plays a critical role in:
FGF21 ensures that neurons maintain the energy required to function, adapt, and recover.
At the core of the protocol is Klotho, a protein strongly associated with extended lifespan and cognitive performance.
Klotho supports:
By restoring Klotho levels, we help preserve neural network integrity, a key determinant of brainspan.
At Blast Longevity, we believe your brain’s potential is not fixed. It is a dynamic, adaptable system waiting to be optimized. Our Brain Enhancement Program is a comprehensive, science-powered protocol designed to not only restore age-related decline but to propel your cognitive function far beyond conventional limits. Achieve unparalleled mental clarity, fortify your neural resilience, and unlock a state of sustained peak performance.
